Cardiac Non-Human Leukocyte Antigen Identification: Techniques and Troubles
Related Experiment Video
Updated: Feb 19, 2026
Isolation and Identification of Extravascular Immune Cells of the Heart
Published on: August 23, 2018
Katherine V Gates1,2, Naveen L Pereira2, Leigh G Griffiths2
1Department of Veterinary Medicine and Epidemiology, University of California, Davis, Davis, CA, United States.
Insights
Non-human leukocyte antigen (HLA) antibodies are increasingly recognized as key drivers of rejection after heart transplants. This review explores technologies for identifying and quantifying these non-HLA antibodies to improve patient outcomes.
Area of Science:
- Immunology
- Transplantation Science
- Biotechnology
Background:
- Historically, human leukocyte antigen (HLA) mismatches were considered the primary cause of cardiac allograft rejection.
- Emerging research highlights the significant role of non-HLA antibodies in initiating and exacerbating antibody-mediated rejection (AMR) and cardiac allograft vasculopathy (CAV).
Purpose of the Study:
- To review and assess current technologies for identifying non-HLA antibodies.
- To explore methods for quantifying non-HLA antibody responses in recipients of cardiac transplants.
Main Methods:
- Review of existing literature on non-HLA antibody detection technologies.
- Analysis of techniques used to identify antigenic targets of non-HLA humoral immune responses.
Main Results:
- Various techniques exist for non-HLA antibody identification, each with distinct advantages and limitations.
- Current methods for detecting non-HLA antibodies provide insights into graft-specific immune responses.
Conclusions:
- Improved detection of non-HLA antibodies is crucial for understanding the pathogenesis of AMR and CAV.
- Advancements in non-HLA antibody detection technologies hold the potential to enhance patient outcomes in cardiac transplantation.
Abstract:
Historically efforts have focused on the human leukocyte antigen (HLA) as the major cause for acute and chronic rejection following cardiac transplantation. However, rising evidence indicates that non-HLA antibodies can be both primary initiators and modifiers of antibody-mediated rejection (AMR) and cardiac allograft vasculopathy (CAV). The purpose of this review is to assess currently available technologies for non-HLA identification and leveraging such responses toward antibody quantification. Several techniques have been used to identify antigenic determinants of recipient graft-specific non-HLA humoral immune responses, but each comes with its own set of benefits and caveats. Improving our ability to detect non-HLA humoral immune response will aid in our understanding of the underlying antigenic determinants of AMR and CAV, as well as improve patient outcomes.
